Non-small cell lung cancer: radiation therapy for locoregional recurrence after complete resection
We investigated patterns of failure after radical radiation therapy in relation to the radiation field in patients with postsurgical locoregional recurrence of non-small cell lung cancer.
Between 1992 and 2002, 31 patients with locoregional recurrence were treated with radiation therapy. At the time of radiation therapy, the sites of recurrence were the bronchial stump, the regional lymph nodes, the chest wall, and both the regional lymph nodes and the chest wall in 7, 20, 3, and 1 patient, respectively. The prescribed dose was 60 Gy in 30 fractions over 6 weeks in all patients.
The response rate was 87%. The overall 1-year, 2-year, and 4-year Kaplan-Meier survival rates were 61%, 30%, and 15%, respectively, and the median survival time was 14 months. Locoregional relapse with or without distant metastasis occurred in 15 patients (in-field, 7; marginal, 7; out-field, 1), and distant metastasis alone occurred in 7 patients. The sites of marginal relapse were the upper margin in two patients, the ipsilateral margin in one patient, the contralateral margin in one patient, and the lower margin in three patients, respectively (in one patient, the data for marginal relapse overlapped). In all patients with relapse on the lower margin, the mediastinal lymph nodes were dissected at the initial surgery.
Postoperative recurrent non-small cell lung cancer showed distinctive features: the response rate was high, and the incidence of marginal relapse was also high, as in small cell lung cancer. The incidence of lower marginal relapse was high, in contrast to that in surgery-naive patients.
Key wordsNon-small-cell lung cancer Radiation therapy Surgery Recurrence
Unable to display preview. Download preview PDF.
- 3.Field, R, Rubinstein, L, Weisenberger, T 1984Site of recurrence in resected stage I non-small cell lung cancer. A guide for future studiesInt J Radiat Oncol Biol Phys213521358Google Scholar
- 12.Cox, JD, Azarnia, N, Byhardt, RW, et al. 1990A randomized phase I/II trial of hyperfractionated radiation therapy with total dose of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11J Clin Oncol815431555PubMedGoogle Scholar
- 13.Vanuytsel, LJ, Vansteenkiste, JF, Stroobants, SG, et al. 2000The impact of (18)F-fluoro-2-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancerRadiother Oncol27317324Google Scholar